169 related articles for article (PubMed ID: 19411627)
21. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
22. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23).
Hilden JM; Frestedt JL; Moore RO; Heerema NA; Arthur DC; Reaman GH; Kersey JH
Blood; 1995 Nov; 86(10):3876-82. PubMed ID: 7579356
[TBL] [Abstract][Full Text] [Related]
23. Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia.
Aoki Y; Watanabe T; Saito Y; Kuroki Y; Hijikata A; Takagi M; Tomizawa D; Eguchi M; Eguchi-Ishimae M; Kaneko A; Ono R; Sato K; Suzuki N; Fujiki S; Koh K; Ishii E; Shultz LD; Ohara O; Mizutani S; Ishikawa F
Blood; 2015 Feb; 125(6):967-80. PubMed ID: 25538041
[TBL] [Abstract][Full Text] [Related]
24. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
25. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias.
Rubnitz JE; Behm FG; Curcio-Brint AM; Pinheiro RP; Carroll AJ; Raimondi SC; Shurtleff SA; Downing JR
Blood; 1996 Jun; 87(11):4804-8. PubMed ID: 8639852
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene.
Elia L; Grammatico S; Paoloni F; Vignetti M; Rago A; Cenfra N; Mecarocci S; Mancini M; Luciani M; Di Raimondo F; Cazzaniga G; Matarazzo M; Moleti ML; Santoro L; Gaidano G; Foà R; Mandelli F; Cimino G
Am J Hematol; 2011 Dec; 86(12):993-7. PubMed ID: 21953510
[TBL] [Abstract][Full Text] [Related]
27. Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report.
Naghashpour M; Lancet J; Moscinski L; Zhang L
Am J Hematol; 2010 Jun; 85(6):451-4. PubMed ID: 20513125
[TBL] [Abstract][Full Text] [Related]
28. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
29. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
[TBL] [Abstract][Full Text] [Related]
30. Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia.
Montes R; Ayllón V; Gutierrez-Aranda I; Prat I; Hernández-Lamas MC; Ponce L; Bresolin S; Te Kronnie G; Greaves M; Bueno C; Menendez P
Blood; 2011 May; 117(18):4746-58. PubMed ID: 21389315
[TBL] [Abstract][Full Text] [Related]
31. Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia.
van der Linden MH; Seslija L; Schneider P; Driessen EM; Castro PG; Stumpel DJ; van Roon E; de Boer J; Williams O; Pieters R; Stam RW
PLoS One; 2015; 10(3):e0120326. PubMed ID: 25793396
[TBL] [Abstract][Full Text] [Related]
32. Analysis of ETV6/RUNX1 fusions for evaluating the late effects of cancer therapy in ALL (acute lymphoblastic leukemia) cured patients.
Brassesco MS; Camparoto ML; Tone LG; Sakamoto-Hojo ET
Cytogenet Genome Res; 2004; 104(1-4):346-51. PubMed ID: 15162063
[TBL] [Abstract][Full Text] [Related]
33. MLL-SEPT5 fusion transcript in infant acute myeloid leukemia with t(11;22)(q23;q11).
Launay E; Henry C; Meyer C; Chappé C; Taque S; Boulland ML; Ben Abdelali R; Dugay F; Marschalek R; Bastard C; Fest T; Gandemer V; Belaud-Rotureau MA
Leuk Lymphoma; 2014 Mar; 55(3):662-7. PubMed ID: 23725386
[TBL] [Abstract][Full Text] [Related]
34. New insights to the MLL recombinome of acute leukemias.
Meyer C; Kowarz E; Hofmann J; Renneville A; Zuna J; Trka J; Ben Abdelali R; Macintyre E; De Braekeleer E; De Braekeleer M; Delabesse E; de Oliveira MP; Cavé H; Clappier E; van Dongen JJ; Balgobind BV; van den Heuvel-Eibrink MM; Beverloo HB; Panzer-Grümayer R; Teigler-Schlegel A; Harbott J; Kjeldsen E; Schnittger S; Koehl U; Gruhn B; Heidenreich O; Chan LC; Yip SF; Krzywinski M; Eckert C; Möricke A; Schrappe M; Alonso CN; Schäfer BW; Krauter J; Lee DA; Zur Stadt U; Te Kronnie G; Sutton R; Izraeli S; Trakhtenbrot L; Lo Nigro L; Tsaur G; Fechina L; Szczepanski T; Strehl S; Ilencikova D; Molkentin M; Burmeister T; Dingermann T; Klingebiel T; Marschalek R
Leukemia; 2009 Aug; 23(8):1490-9. PubMed ID: 19262598
[TBL] [Abstract][Full Text] [Related]
35. A novel infant acute lymphoblastic leukemia cell line with MLL-AF5q31 fusion transcript.
Imamura T; Morimoto A; Ikushima S; Kakazu N; Hada S; Tabata Y; Yagi T; Inaba T; Hibi S; Sugimoto T; Imashuku S
Leukemia; 2002 Nov; 16(11):2302-8. PubMed ID: 12399976
[TBL] [Abstract][Full Text] [Related]
36. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.
van der Linden MH; Willekes M; van Roon E; Seslija L; Schneider P; Pieters R; Stam RW
Cell Cycle; 2014; 13(5):834-44. PubMed ID: 24736461
[TBL] [Abstract][Full Text] [Related]
37. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by
Chu SH; Song EJ; Chabon JR; Minehart J; Matovina CN; Makofske JL; Frank ES; Ross K; Koche RP; Feng Z; Xu H; Krivtsov A; Nussenzweig A; Armstrong SA
Blood Adv; 2018 Oct; 2(19):2478-2490. PubMed ID: 30266823
[TBL] [Abstract][Full Text] [Related]
39. Fetal liver Mll-AF4+ hematopoietic stem and progenitor cells respond directly to poly(I:C), but not to a single maternal immune activation.
Malouf C; Ottersbach K
Exp Hematol; 2019 Aug; 76():49-59. PubMed ID: 31381950
[TBL] [Abstract][Full Text] [Related]
40. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.
Silverman LB; McLean TW; Gelber RD; Donnelly MJ; Gilliland DG; Tarbell NJ; Sallan SE
Cancer; 1997 Dec; 80(12):2285-95. PubMed ID: 9404706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
